Cybin announces additional u.s. patent supporting its cyb003 breakthrough therapy program in phase 3 development for major depressive disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the united states patent and trademark office has granted u.s. patent 12,291,499 in support of its cyb003 program in mdd. the patent, which is expected to provide exclusivity until 2041, includes cla.
CYBN Ratings Summary
CYBN Quant Ranking